Generic Name:
ixekizumab
Project Status:
Complete
Therapeutic Area:
Ankylosing spondylitis
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Taltz
Project Line:
Reimbursement Review
Project Number:
SR0630-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.
Submission Type:
Initial
Fee Schedule:
Schedule B
Indications:
Ankylosing spondylitis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.